Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 4/2016

01-04-2016 | Prostate Cancer (A Kibel, Section Editor)

Prostate Cancer Prevention: Concepts and Clinical Trials

Authors: Zachary Hamilton, J. Kellogg Parsons

Published in: Current Urology Reports | Issue 4/2016

Login to get access

Abstract

Prevention is an important treatment strategy for diminishing prostate cancer morbidity and mortality and is applicable to both early- and late-stage disease. There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatment of preclinical disease), and tertiary (prevention of progression or recurrence). Based on level I evidence, 5-alpha reductase inhibitors (5-ARIs) should be considered in selected men to prevent incident prostate cancer. Level I evidence also supports the consideration of dutasteride, a 5-ARI, for tertiary prevention in active surveillance and biochemical recurrence patients. Vitamins and supplements, including selenium or vitamin E, have not been proven in clinical trials to prevent prostate cancer and in the case of Vitamin E has been found to increase the risk of incident prostate cancer. Ongoing and future trials may further elucidate the role of diet and immunotherapy for prevention of prostate cancer.
Literature
1.
2.
Tao ZQ, Shi AM, Wang KX, Zhang WD. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015;19(5):805–12.PubMed
3.
Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol. 2013;23:331–6.CrossRefPubMed
4.
Moyer VA. U.S. Preventive Services Task Force. screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.CrossRefPubMed
5.
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.CrossRefPubMed
6.
Silberstein JL, Parsons JK. Prostate cancer prevention: concepts and clinical recommendations. Prostate Cancer Prostatic Dis. 2010;13(4):300–6.CrossRefPubMed
7.
Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, et al. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene. 2005;24:5868–77.CrossRefPubMed
8.
Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate. 2006;66:1070–5.CrossRefPubMed
9.
van den Brandt PA, Zeegers MPA, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2003;12:866–71.PubMed
10.
Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91:608–12.CrossRefPubMed
11.
Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8:893–9.PubMed
12.
Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst. 2006;98:245–54.CrossRefPubMed
13.•
Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51. This was a phase III trial with over 35,000 men examining natural substances (selenium and vitamin E) for chemoprevention of prostate cancer. After 7 years of follow up, no significant benefit was seen for either substance. With additional follow up, there was a small but significantly increased risk of prostate cancer in the vitamin E group. CrossRefPubMedPubMedCentral
14.
Klein EA, Thompson Jr IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.CrossRefPubMedPubMedCentral
15.
Stevens VL, McCullough ML, Diver WR, et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control. 2005;16(6):643–50.CrossRefPubMed
16.
Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301:52–62.CrossRefPubMedPubMedCentral
17.
Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol. 2008;53:244–52.CrossRefPubMed
18.
Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology. 1995;136:741–8.PubMed
19.•
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24. This was a phase III trial evaluating the use of finasteride for prevention of prostate cancer over a 7 year follow up period. Over 18,000 men (at least 55 years old, PSA ≤ 3 ng/ml, normal DRE) were enrolled with for-cause biopsy or end-of-study biopsy performed. There was a 25 % relative risk reduction in prostate cancer detection associated with finasteride, although higher grade disease was diagnosed more frequently in the finasteride cohort. CrossRefPubMed
20.
Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375–83.CrossRefPubMed
21.
Mellon JK. The finasteride Prostate Cancer Prevention Trial (PCPT) – what have we learned? Eur J Cancer. 2005;41:2016–22.CrossRefPubMed
22.
Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10:149–54.CrossRefPubMed
23.•
Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202. This was a phase III trial evaluating the use of dutasteride for prevention of prostate cancer over a 4 year period. 8000 men (50–75 years old, PSA 2.5–10 ng/ml, negative prostate biopsy within 6 months of enrollment) were screened every 6 months with for-cause biopsy or planned biopsy at 2 and 4 years performed. There was a 23 % relative risk reduction associated with dutasteride and an increased incidence of high grade disease in the dutasteride cohort. This confirmed the findings of the PCPT trial. CrossRefPubMed
24.
Lacy JM, Kyprianou N. A tale of two trials: the impact of 5α-reductase inhibition on prostate cancer (review). Oncol Lett. 2014;8(4):1391–6.PubMedPubMedCentral
25.
Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(2):97–9.CrossRefPubMed
26.
Kim J, Amos CI, Logothetis C. 5α-Reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(24):2340.CrossRefPubMed
27.
Welch HG, Gorski DH, Albertsen PC. Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med. 2015;373(18):1685–7.CrossRefPubMed
28.
Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17:3167–72.PubMed
29.
Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955–63.CrossRefPubMedPubMedCentral
30.
31.
Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(9):1211–9. quiz 1219.PubMed
32.
Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.CrossRefPubMed
33.
34.
Schröder FH, Hugosson J, Roobol MJ. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.CrossRefPubMedPubMedCentral
35.
Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Onc. 2010;11:725–32.CrossRef
36.
Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–32.CrossRefPubMedPubMedCentral
37.
38.
Grubb RL, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008;102(11):1524–30.CrossRefPubMed
39.•
Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1103–11. This phase III trial evaluated the use of dutasteride in an active surveillance cohort, enrolling 302 men with low risk prostate cancer and following them over a 3 year period with planned biopsies performed at 1.5 and 3 years. There was a 38 % relative risk reduction in pathologic and therapeutic progression in the dutasteride cohort, although it was unclear if this was due to a true medication effect or instead due to reductions in patient/provider treatment anxiety given that dutasteride lowers PSA values and improves PSA operating characteristics. CrossRefPubMed
40.
Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128–33.CrossRefPubMed
41.
Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178(3 Pt 1):826–31. discussion 831-2.CrossRefPubMed
42.
Schröder F, Bangma C, Angulo JC, et al. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol. 2013;63(5):779–87.CrossRefPubMed
43.
Ehdaie B, Touijer KA. 5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice. Eur Urol. 2013;63(5):788–9. discussion 790-1.CrossRefPubMed
44.
Parsons JK, Pierce JP, Mohler J, et al. A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men’s Eating and Living (MEAL) Study. Contemp Clin Trials. 2014;38(2):198–203.CrossRefPubMedPubMedCentral
45.
46.
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9.CrossRefPubMed
47.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.CrossRefPubMed
48.
Gulley JL, Heery CR, Madan RA, et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother. 2013;62(9):1521–31.CrossRefPubMed
49.
Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–105.CrossRefPubMedPubMedCentral
50.
Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol. 2009;16(5):4806–12.PubMed
51.
Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1–160.
52.
Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol, Biomarkers Prevent: Public Am Assoc Cancer Res, Cosponsored Am Soc Prevent Oncol. 2008;17:88–94.CrossRef
53.
Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959–68.CrossRefPubMedPubMedCentral
54.
55.
Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008;168:250–60.CrossRefPubMedPubMedCentral
56.
Platz EA, Tangen CM, Goodman PJ, et al. Statin drug use is not associated with prostate cancer risk in men who are regular screened. Urology. 2014;192(2):379–84.CrossRef
57.
Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004;172:S6–11. discussion S11-12.CrossRefPubMed
58.
59.
Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30:3540–4.CrossRefPubMedPubMedCentral
60.
Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97:975–80.CrossRefPubMed
Metadata
Title
Prostate Cancer Prevention: Concepts and Clinical Trials
Authors
Zachary Hamilton
J. Kellogg Parsons
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Urology Reports / Issue 4/2016
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-016-0587-1

Other articles of this Issue 4/2016

Current Urology Reports 4/2016 Go to the issue

Female Urology (K Kobashi, Section Editor)

Management of the Recurrent Male Urethral Stricture

Female Urology (K Kobashi, Section Editor)

Female Bladder Outlet Obstruction

Prostate Cancer (A Kibel, Section Editor)

Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer

Female Urology (K Kobashi, Section Editor)

Mesh Excision: Is Total Mesh Excision Necessary?

Female Urology (K Kobashi, Section Editor)

Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA

Female Urology (K Kobashi, Section Editor)

Female Sexual Dysfunction: Is It a Treatable Disease?